4D Molecular Therapeutics (FDMT) Assets Average (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Assets Average data on file, last reported at $539.8 million in Q1 2026.

• Assets Average for Q1 2026 came in at $539.8 million, changed 0.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $539.8 million (changed 0.33% YoY), and the FY2025 annual result was $563.5 million, up 25.19% from the prior year.
• Assets Average improved to $539.8 million in Q1 2026 per FDMT's latest filing, from $495.3 million in the prior quarter.
• Over five years, Assets Average peaked at $625.0 million in Q2 2024 and troughed at $252.9 million in Q1 2023.
• A 5-year average of $429.2 million and a median of $448.8 million in 2025 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2025: Assets Average soared 109.55% in 2024, then fell 26.67% in 2025.
• A 5-year view of Assets Average shows it stood at $271.0 million in 2022, then advanced by 29.43% to $350.8 million in 2023, then jumped by 65.99% to $582.2 million in 2024, then declined by 14.92% to $495.3 million in 2025, then gained by 8.98% to $539.8 million in 2026.
• Business Quant data shows FDMT's Assets Average at $539.8 million in Q1 2026, $495.3 million in Q4 2025, and $448.8 million in Q3 2025.